604 related articles for article (PubMed ID: 11654756)
41. On studying the powerful (or fearing to do so): a vital role for IRBs.
Sieber JE
IRB; 1989; 11(5):1-6. PubMed ID: 11650252
[No Abstract] [Full Text] [Related]
42. The tissue issue: losing oneself to science?
Strauss E
Sci News; 1997 Sep; 152(12):190-1. PubMed ID: 11655157
[No Abstract] [Full Text] [Related]
43. Banking biological collections.
Blatt RJ
J Biolaw Bus; 1998; 2(1):3-4. PubMed ID: 11657636
[No Abstract] [Full Text] [Related]
44. Drug trials hide conflicts for doctors.
Eichenwald K; Kolata G
N Y Times Web; 1999 May; ():1, 34. PubMed ID: 11648114
[No Abstract] [Full Text] [Related]
45. Biotechnology and the commercial use of human cells: toward an organic view of life and technology.
Martin PA; Lagod ML
Santa Clara Comput High Technol Law J; 1989 Jun; 5(2):211-61. PubMed ID: 11659674
[No Abstract] [Full Text] [Related]
46. Beyond Moore: issues of law and policy impacting human cell and genetic research in the age of biotechnology.
Hartman RG
J Leg Med; 1993 Sep; 14(3):463-77. PubMed ID: 7779167
[No Abstract] [Full Text] [Related]
47. Informed consent in psychiatric research.
Roth LH; Appelbaum PS; Lidz CW; Benson P; Winslade WJ
Rutgers Law Rev; 1987; 39(2-3):425-41. PubMed ID: 11659013
[No Abstract] [Full Text] [Related]
48. Commercial tissue repositories: HIPAA raises sponsors' fears.
Allen MD
IRB; 2004; 26(5):9-11. PubMed ID: 15658012
[No Abstract] [Full Text] [Related]
49. Informed consent is binding contract: Dahl v. HEM Pharmaceuticals.
Maloney DM
Hum Res Rep; 1995 Dec; 10(12):4-5. PubMed ID: 11653220
[No Abstract] [Full Text] [Related]
50. Moore v. The Regents of the University of California: an ethical debate on informed consent and property rights in a patient's cells.
Prowda JB
J Pat Trademark Off Soc; 1995 Aug; 77(8):611-39. PubMed ID: 11658094
[No Abstract] [Full Text] [Related]
51. From control over one's body to control over one's body parts: extending the doctrine of informed consent.
Perley SN
N Y Univ Law Rev; 1992 May; 67(2):335-65. PubMed ID: 11659626
[No Abstract] [Full Text] [Related]
52. Rethinking research ethics.
Rhodes R
Am J Bioeth; 2005; 5(1):7-28. PubMed ID: 16036651
[TBL] [Abstract][Full Text] [Related]
53. Public policy symposium: the legal, ethical, and economic impact of patient material used for product development in the biomedical industry.
Royston I; Wagner AB; Caplan AL; Rosenberg LE
Clin Res; 1985 Oct; 33(4):442-58. PubMed ID: 11643828
[No Abstract] [Full Text] [Related]
54. How not to rethink research ethics.
Beauchamp TL
Am J Bioeth; 2005; 5(1):31-3; author reply W15-8. PubMed ID: 16036653
[No Abstract] [Full Text] [Related]
55. "Dear Mrs. X.
Davis DS
IRB; 1983; 5(6):6-9. PubMed ID: 11649528
[No Abstract] [Full Text] [Related]
56. Vulnerable subjects and Canadian research governance.
Wilson M
IRB; 2005; 27(6):9-11. PubMed ID: 16425479
[No Abstract] [Full Text] [Related]
57. The commercialization of human tissue -- the source of legal, ethical and social problems: an area better suited to legislative resolution.
O'Connor JJ
Loyola Los Angel Law Rev; 1990 Nov; 24(1):115-69. PubMed ID: 11659354
[No Abstract] [Full Text] [Related]
58. Structuring the review of human genetics protocols: gene localization and identification studies.
Glass KC; Weijer C; Palmour RM; Shapiro SH; Lemmens TM; Lebacqz K
IRB; 1996; 18(4):1-9. PubMed ID: 11654877
[No Abstract] [Full Text] [Related]
59. Human fetal tissue for medical research.
Tuch BE
Med J Aust; 1993 May; 158(8):637-9. PubMed ID: 11659709
[No Abstract] [Full Text] [Related]
60. The ethical uses of human tissue.
Berry C
Br J Hosp Med; 1995 Oct 18-31; 54(8):367-8, 370. PubMed ID: 8535586
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
